🦠Exclusive License Opportunity for Engineered Commensal Bacteria Technology
Prospective Grant of Exclusive, Inter-Institutional Agreement-Institution Lead: Generation of Antigen-Specific T and B Cells Using Engineered Commensals
Summary
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Inter- Institutional Agreement-Institution Lead to CZ Biohub SF, LLC ("CZB"), located in San Francisco, California, in its rights to the technologies and patent applications listed in the Supplementary Information section of this notice.
Agencies
- Health and Human Services Department
- National Institutes of Health
Business Impact
$$$ - High
The content discusses a prospective grant of an exclusive agreement revolving around the licensing of significant patent rights for technology related to engineered commensal bacteria and immune response modulation. This can present business opportunities in biotechnology and immunology for companies interested in these advancements.